Mr. Barrow is an accomplished pharmaceutical executive and clinical pharmacologist with over a decade of experience leading drug development programs in a variety of disease areas. After joining MindMed as Chief Development Officer in January 2021, he was named CEO in June 2021.
Mr. Barrow previously served as Director of Drug Development & Discovery at Usona Institute, where he oversaw preclinical, clinical and regulatory development efforts for all of Usona’s development programs. Prior to joining Usona, Mr. Barrow served as Chief Operating Officer of Olatec Therapeutics, LLC, a private, clinical-stage biopharmaceutical company, where he oversaw the execution of numerous early- and late-stage clinical trials in the fields of analgesics, rheumatology, immunology and cardiovascular disease. In addition, he has been responsible for the design and execution of preclinical research programs for new molecular entity drugs in CNS conditions such as multiple sclerosis, Alzheimer’s Disease and Parkinson’s Disease.
Mr. Barrow has also served as both a technical and business adviser to numerous pharmaceutical organizations ranging from startups to Fortune 500 companies.
Mr. Barrow holds a Masters degree in Pharmacology from The Ohio State University and a Bachelor of Science degree from Wake Forest University, where he graduated summa cum laude and is a CFA charterholder.
What is Robert Barrow's net worth?
The estimated net worth of Robert Barrow is at least $56.27 million as of September 3rd, 2026. Mr. Barrow owns 1,494,640 shares of Definium Therapeutics stock worth more than $56,273,196 as of September 23rd. This net worth approximation does not reflect any other assets that Mr. Barrow may own. Learn More about Robert Barrow's net worth.
How do I contact Robert Barrow?
Has Robert Barrow been buying or selling shares of Definium Therapeutics?
In the last ninety days, Robert Barrow has sold $721,732.62 of Definium Therapeutics stock. Most recently, Robert Barrow sold 19,023 shares of the business's stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $37.94, for a transaction totalling $721,732.62. Following the completion of the sale, the chief executive officer now directly owns 1,494,640 shares of the company's stock, valued at $56,706,641.60. Learn More on Robert Barrow's trading history.
Who are Definium Therapeutics' active insiders?
Are insiders buying or selling shares of Definium Therapeutics?
During the last twelve months, insiders at the sold shares 11 times. They sold a total of 154,565 shares worth more than $3,886,057.38. The most recent insider tranaction occured on September, 3rd when CEO
Robert Barrow sold 19,023 shares worth more than $721,732.62. Insiders at Definium Therapeutics own 2.4% of the company.
Learn More about insider trades at Definium Therapeutics. Information on this page was last updated on 9/3/2026.
